此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Cardiac COVID-19 Health Care Workers (CCC)

2020年6月13日 更新者:Pedro L Sanchez、AORTICA Group

Cardiac Involvement in Coronavirus (SARS-Cov-2) Infected Health Care Workers: The CCC Study

The study will analyze the prevalence of cardiac involvement of health care workers from the University Hospital of Salamanca (HUSA) who have overcome SARS-CoV-2 infection. Participants will undergo a clinical evaluation, electrocardiogram (EKG), cardiac magnetic resonance (CMR) and blood analysis including NT-proBNP, troponin, cellular and humoral immunity and genetics.

研究概览

详细说明

Most people infected with SARS-CoV-2 experience mild, self-limiting symptoms that have been managed in an outpatient setting and therefore have not undergone routine cardiac evaluation with EKG or cardiac imaging test. Similarly, although the emphasis has been placed on evaluating patients with severe respiratory symptoms, most of these patients have also not undergone cardiac imaging tests and; therefore, in both scenarios, possible myocarditis has not routinely evaluated.

The present study is designed to characterize cardiac involvement in individuals who have overcome the SARS-CoV-2 infection.

For that aim, the study is designed as an observational cross-sectional study. The target population are HUSA healthcare workers who have overcome SARS-CoV-2 infection, either symptomatic or asymptomatic, either having required hospital admission or not. Participants will undergo a clinical evaluation, electrocardiogram (EKG), cardiac magnetic resonance (CMR) and blood analysis including NT-proBNP, troponin, cellular and humoral immunity and genetics.

Main objectives of the study are to address the prevalence of myocardial damage suggestive of myocarditis and to address the prevalence of pericarditis in HUSA health care workers; both related to the systemic immune response to SARS-CoV-2 infection. As secondary objectives the study will further address other cardiac affections including: rhythm or conduction disorders, ischemic heart disease, dilatation of the right chambers, valve disease and will analyze the relationship between humoral and cellular immunity and the presence of cardiac involvement, and the genetic susceptibility in the development of cardiac involvement after SARS-CoV-2 infection.

The study will recruit 141 participants: 47 symptomatic hospitalized health care workers, 47 asymptomatic non-hospitalized health care workers, 47 asymptomatic health care workers

研究类型

观察性的

注册 (实际的)

142

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

      • Salamanca、西班牙、37007
        • University Hospital of Salamanca

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 71年 (成人、年长者)

接受健康志愿者

有资格学习的性别

全部

取样方法

概率样本

研究人群

The target population are Salamanca´s healthcare workers who have overcome SARS-CoV-2 infection, either symptomatic or asymptomatic, either having required hospital admission or not.

描述

Inclusion Criteria:

  • Have overcome the SARS-CoV-2 infection meeting any of the following criteria (i) positive result on a reverse-transcriptase-polymerase-chain-reaction (RT-PCR) assay of a specimen collected on a nasopharyngeal swab followed by a second negative RT-PCR and at least 14 days from this negative RT-PCR; (ii) presence of IgM antibodies and negative RT-PCR after the antibody assessment; (iii) presence of neutralizing IgG antibodies and absence of IgM.
  • stable clinical situation, which allows performing a CMR.
  • signature of informed consent.

Exclusion Criteria:

  • Presence of IgM antibodies without negative subsequent RT-PCR.
  • Contraindications to perform RMC: (i) gadolinium allergy, (ii) presence of metallic material in the body, such as plates, screws, incompatible pacemakers, etc. (iii) claustrophobia, (iv) severe kidney failure, (v) severe liver failure, (vi) sickle cell anemia

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 观测模型:队列
  • 时间观点:横截面

队列和干预

团体/队列
干预/治疗
Health care workers
Health care workers from the University Hospital of Salamanca who have passed SARS-CoV-2 infection.
This is an observational design. Participants have passed infection from SARS-CoV-2 and a cardiac assessment is performed.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Myocarditis
大体时间:up to 3 months
Prevalence of myocardial damage suggestive of myocarditis assessed by cardiac magnetic resonance
up to 3 months
Pericarditis
大体时间:up to 3 months
Prevalence of pericarditis assessed by clinical criteria
up to 3 months

次要结果测量

结果测量
措施说明
大体时间
Atrial fibrillation
大体时间:up to 3 months
Prevalence of atrial fibrillation on EKG
up to 3 months
Ischemic heart disease
大体时间:up to 3 months
Prevalence of ischemic heart disease assessed by cardiac magnetic resonance
up to 3 months
Dilatation of right heart chambers
大体时间:up to 3 months
Prevalence of dilatation of right heart chambers assessed by cardiac magnetic resonance
up to 3 months
Valvular hear disease
大体时间:up to 3 months
Prevalence of valvular heart disease assessed by cardiac magnetic resonance
up to 3 months
Rhythm disorders
大体时间:up to 3 months
Prevalence of prolonged QT interval on EKG
up to 3 months

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2020年5月25日

初级完成 (实际的)

2020年6月12日

研究完成 (实际的)

2020年6月12日

研究注册日期

首次提交

2020年5月23日

首先提交符合 QC 标准的

2020年6月1日

首次发布 (实际的)

2020年6月2日

研究记录更新

最后更新发布 (实际的)

2020年6月16日

上次提交的符合 QC 标准的更新

2020年6月13日

最后验证

2020年6月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

未定

药物和器械信息、研究文件

研究美国 FDA 监管的药品

研究美国 FDA 监管的设备产品

在美国制造并从美国出口的产品

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

新冠肺炎的临床试验

Passed infection of SARS-CoV-2的临床试验

3
订阅